BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7989744)

  • 21. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
    Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
    J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The inability of the nonobese diabetic class II molecule to form stable peptide complexes does not reflect a failure to interact productively with DM.
    Peterson M; Sant AJ
    J Immunol; 1998 Sep; 161(6):2961-7. PubMed ID: 9743359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptor-mediated endocytosis of antigens overcomes the requirement for HLA-DM in class II-restricted antigen presentation.
    Ma C; Blum JS
    J Immunol; 1997 Jan; 158(1):1-4. PubMed ID: 8977167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The intracellular transport of MHC class II molecules in the absence of HLA-DM.
    Green JM; DeMars R; Xu X; Pierce SK
    J Immunol; 1995 Oct; 155(8):3759-68. PubMed ID: 7561080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ek beta mutant antigen-presenting cell lines expressing altered Ak alpha molecules.
    Quill H; Schwartz RH; Glimcher LH
    J Immunol; 1986 May; 136(9):3351-9. PubMed ID: 3082986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants.
    Monji T; McCormack AL; Yates JR; Pious D
    J Immunol; 1994 Nov; 153(10):4468-77. PubMed ID: 7525705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells.
    Fling SP; Arp B; Pious D
    Nature; 1994 Apr; 368(6471):554-8. PubMed ID: 8139690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unexpected reactivities of T cells selected by a single MHC-peptide ligand.
    Singh N; Van Kaer L
    J Immunol; 1999 Oct; 163(7):3583-91. PubMed ID: 10490950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
    Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
    J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct antigen MHC class II complexes generated by separate processing pathways.
    Lindner R; Unanue ER
    EMBO J; 1996 Dec; 15(24):6910-20. PubMed ID: 9003767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells.
    Bertolino P; Rabourdin-Combe C
    Crit Rev Immunol; 1996; 16(4):359-79. PubMed ID: 8954255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides.
    Riberdy JM; Newcomb JR; Surman MJ; Barbosa JA; Cresswell P
    Nature; 1992 Dec; 360(6403):474-7. PubMed ID: 1448172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DM-mediated release of a naturally occurring invariant chain degradation intermediate from MHC class II molecules.
    Stebbins CC; Peterson ME; Suh WM; Sant AJ
    J Immunol; 1996 Dec; 157(11):4892-8. PubMed ID: 8943393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines.
    Weenink S; Averdunk H; Boston T; Boswarva V; Guery JC; Adorini L; Mellins E; McCluskey J; Gautam AM
    Int Immunol; 1997 Jun; 9(6):889-96. PubMed ID: 9199972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.
    Clements VK; Baskar S; Armstrong TD; Ostrand-Rosenberg S
    J Immunol; 1992 Oct; 149(7):2391-6. PubMed ID: 1527384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invariant chain expression similarly controls presentation of endogenously synthesized and exogenous antigens by MHC class II molecules.
    Lombard-Platet S; Bertolino P; Gimenez C; Humbert M; Gerlier D; Rabourdin-Combe C
    Cell Immunol; 1993 Apr; 148(1):60-70. PubMed ID: 8495491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polarized transport of MHC class II molecules in Madin-Darby canine kidney cells is directed by a leucine-based signal in the cytoplasmic tail of the beta-chain.
    Simonsen A; Pedersen KW; Nordeng TW; von der Lippe A; Stang E; Long EO; Bakke O
    J Immunol; 1999 Sep; 163(5):2540-8. PubMed ID: 10452991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DMA and DMB are the only genes in the class II region of the human MHC needed for class II-associated antigen processing.
    Ceman S; Rudersdorf RA; Petersen JM; DeMars R
    J Immunol; 1995 Mar; 154(6):2545-56. PubMed ID: 7876531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.